Todd Foley
Managing Director at MPM BioImpact
About
Managing Director who joined the firm in 1999. Serves as Chairman of multiple portfolio company boards and has guided significant M&A outcomes including Semma Therapeutics acquisition by Vertex for $950M and Selexys acquisition by Novartis for $665M.
Investments
Board seats
Aktis Oncology, Inc.Entrada Therapeutics, Inc.Tetherex Pharmaceuticals Corp
As listed on the firm's website.
Colleagues at MPM BioImpact
Andrew Scharenberg
Entrepreneur Partner at MPM BioImpact
Ansbert Gadicke
Managing Partner at MPM BioImpact
Ansbert Gadicke, M.D.
Chairman at MPM BioImpact
Aparna Parikh
Entrepreneur Partner at MPM BioImpact
Binsen Li
Principal at MPM BioImpact
Brendan Furey
Chief Compliance Officer at MPM BioImpact
Brian Shuster
Entrepreneur Partner at MPM BioImpact
Briggs Morrison
Entrepreneur Partner at MPM BioImpact